歡迎光臨源葉生物,登錄 | 注冊 |
當前位置: 首頁 > 小分子抑制劑 > PI3K/Akt/mTORsignaling > CH5132799

瀏覽歷史

S80011

CH5132799

源葉(MedMol) ≥97%
  • 英文名:
  • CH5132799
  • 別名:
  • 5-(7-(methylsulfonyl)-2-morpholino-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrimidin-2-amine
  • CAS號:
  • 1007207-67-1
  • 分子式:
  • C15H19N7O3S
  • 分子量:
  • 377.42
品牌貨號產(chǎn)品規(guī)格價格(RMB) 庫存(上海) 北京 武漢 南京 數(shù)量計量單位 加入購物車...
源葉(MedMol) S80011-1mg ≥97% ¥264.00元 10 - - - EA 加入購物車
源葉(MedMol) S80011-5mg ≥97% ¥380.00元 10 - - - EA 加入購物車
源葉(MedMol) S80011-10mg ≥97% ¥610.00元 10 - - - EA 加入購物車
源葉(MedMol) S80011-25mg ≥97% ¥960.00元 10 - - - EA 加入購物車
源葉(MedMol) S80011-50mg ≥97% ¥1540.00元 10 - - - EA 加入購物車
源葉(MedMol) S80011-100mg ≥97% ¥2470.00元 3 - - - EA 加入購物車
大包裝詢價

提交您的電話號碼并同意《個人信息授權(quán)與保護申明》,到貨后將短信提示。
提交

產(chǎn)品介紹

參考文獻

質(zhì)檢證書(COA)

摩爾濃度計算器

相關(guān)產(chǎn)品

  • 提示:詳情請下載說明書。
  • 產(chǎn)品描述: Izorlisib (CH5132799) is a selective class I PI3K inhibitor. Izorlisib inhibits class I PI3Ks, particularly PI3Kα, with an IC50 of 14 nM.
  • 靶點: PI3Kα:14 nM (IC50);PI3Kα-H1047R:5.6 nM (IC50);PI3Kα-E545K:6.7 nM (IC50);PI3Kα-E542K:6.7 nM (IC50);PI3Kγ:36 nM (IC50);PI3Kβ:120 nM (IC50);PI3Kδ:500 nM (IC50);PI3KC2β:5.3 μM (IC50);mTOR:1.6 μM (IC50);PI3K;mTOR
  • 體內(nèi)研究:
    Mice bearing BT-474 tumors (n=14) are orally administered 50 mg/kg of Everolimus on a daily basis for 31 days and then randomized. After randomization, the mice are orally administered 50 mg/kg of Everolimus (n=4) and 12.5 mg/kg (n=5), and 25 mg/kg (n=5) of Izorlisib on a daily basis for 7 days. C, the vehicle-, Everolimus, and CH5132799-treated (25 mg/kg) tumors are resected at 4 hours after terminal administration in B, lysed, and analyzed by Western blotting. Izorlisib administration leads to a remarkable regression in a dose-dependent manner of the tumors regrown after the long-term Everolimus treatment. The tumors are resected at the end of treatment and analyzed by Western blotting with respect to PI3K pathway inhibition. Izorlisib suppresses various effectors in the PI3K pathway, including Akt, FoxO1, S6K, S6, and 4E-BP1, whereas Everolimus inhibits only phosphorylation of S6K and S6, both downstream effectors of mTORC1
  • 參考文獻:
    1. Tanaka H, et al. The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations. Clin Cancer Res, 2011, 17(10), 3272-3281. 2. Ohwada J, et al. Discovery and biological activity of a novel class I PI3K inhibitor, CH5132799. Bioorg Med Chem Leff, 2011, 21(6), 1767-1772.
  • 溶解性: Soluble  in  DMSO
  • 保存條件: -20℃
  • 配置溶液濃度參考:
    1mg 5mg 10mg
    1 mM 2.65 ml 13.248 ml 26.496 ml
    5 mM 0.53 ml 2.65 ml 5.299 ml
    10 mM 0.265 ml 1.325 ml 2.65 ml
    50 mM 0.053 ml 0.265 ml 0.53 ml
  • 注意:部分產(chǎn)品我司僅能提供部分信息,我司不保證所提供信息的權(quán)威性,僅供客戶參考交流研究之用。
輸入產(chǎn)品批號:

本計算器可幫助您計算出特定溶液中溶質(zhì)的質(zhì)量、溶液濃度和體積之間的關(guān)系,公式為:


質(zhì)量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)


  • =
    *
    *


源葉所有產(chǎn)品僅用作科學研究,銷售產(chǎn)品行為均適用于我司網(wǎng)上所列通用銷售條款。